Pfizer Inc today announced that its investigational novel COVID-19 oral antiviral candidate PAXLOVID was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19: Pfizer Inc— Prasar Bharati News Services рдкреА.рдмреА.рдПрди.рдПрд╕. (@PBNS_India) November 5, 2021
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


